Methods and kits for classifying solid cancer-afflicted patients based on relb labelling
OwnerVéronique BAUD, Baptiste ELUARDinventors
Life of this patent
Estimating the term…
Abstract
An in vitro method belonging to the field of medicine, more specifically the field of cancer prognostic and therapeutic management, is disclosed. The method is for classifying a subject afflicted with a solid cancer as having a good prognosis or a poor prognosis. The method comprises detecting in a cancer cell sample from the subject phosphorylated RelB protein at the serine residue 472 and/or detecting a RelB homolog phosphorylated at a corresponding serine. A kit for implementing the method also is disclosed.
Claims19
An in vitro method for classifying a subject afflicted with a solid cancer as having a good prognosis or a poor prognosis, comprising detecting in a cancer cell sample from the subject phosphorylated RelB protein of SEQ ID NO:1 at the serine residue 472 and/or detecting a RelB homolog phosphorylated at a corresponding serine.
A kit comprising:
- an antibody, or a fragment thereof, which binds the phosphorylated RelB protein of SEQ ID NO:1 at the serine residue 472 and/or a RelB homolog phosphorylated at a corresponding serine, and
- an instruction to allow classification of the subject afflicted with cancer as having a good prognosis or a poor prognosis by detecting nuclear and/or cytoplasmic labelling with the antibody or fragment thereof.
Dependencies are inferred from the claim text.